Marinus Pharmaceuticals, Inc.

Total Valuation

Marinus Pharmaceuticals, Inc. carries a market capitalization of 30.37M, placing it among publicly traded companies globally. Its enterprise value stands at 114.21M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Marinus Pharmaceuticals, Inc. currently has 55.19M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 3.19, and the price-to-book ratio stands at -0.15.

Enterprise Valuation

Financial Position

Marinus Pharmaceuticals, Inc. maintains a current ratio of 1.66, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -83.90, indicating conservative leverage, while an interest coverage ratio of -7.14 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Stock Price Statistics

Marinus Pharmaceuticals, Inc.'s stock has declined approximately -76.2931% over the past 52 weeks. The 50-day moving average sits at 0.43, while the 200-day moving average is 1.06.

Income Statement

Over the trailing twelve months, Marinus Pharmaceuticals, Inc. generated 31.47M in revenue and converted that into -140.49M in net income, yielding earnings per share of -2.46. EBITDA reached -122.09M, while operating income came in at -122.62M.

Balance Sheet

Marinus Pharmaceuticals, Inc. holds 42.18M in cash and equivalents against 55.99M in total debt, resulting in a net debt position of 13.00M. Total book value stands at -670.59M, with working capital of 22.90M providing operational flexibility.

Cash Flow

Marinus Pharmaceuticals, Inc. produced -114.75M in operating cash flow over the past twelve months. After subtracting -1.15M in capital expenditures, free cash flow totaled -115.89M - equivalent to -2.03 per share.

Margins

Marinus Pharmaceuticals, Inc. operates with a gross margin of 90.17, reflecting its pricing power and cost economics. The operating margin of -389.70 and net profit margin of -446.49 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Marinus Pharmaceuticals, Inc.'s most recent stock split took place on September 23, 2020 with a 4:1 split ratio.

Scores

Marinus Pharmaceuticals, Inc. posts an Altman Z-Score of -19.73, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.